Oryzon Genomics (BME: ORY)

Last close As at 27/03/2024

EUR1.71

0.00 (0.00%)

Market capitalisation

EUR107m

Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset Vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder, and is in a Phase IIb trial for schizophrenia.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and a potentially favourable safety/efficacy profile compared with the first-generation HDAC inhibitors.

Latest Insights

View More

Healthcare | Update

Oryzon Genomics — Approaching a period of inflection

Healthcare | Update

Oryzon Genomics — PORTICO update with planned FDA EoP2

Healthcare | edison tv

Executive interview with Carlos Buesa, CEO of Oryzon Genomics

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Carlos Buesa

    CEO

Balance Sheet

Forecast net cash (€m)

19.1

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual (8.3) (16.0) (19.1)
Relative (15.4) (22.7) (35.3)
52 week high/low €2.4/€1.6

Financials

ORY FY23 results announcement covered an eventful period for the company’s pipeline, capped by the release of top-line data from the Phase IIb PORTICO trial for lead CNS asset vafidemstat. With the focus squarely on the planned end of Phase II (EoP2) meeting with the FDA and anticipated clinical updates on the remaining programmes, we see FY24 as a crucial period for the company, with multiple inflection points. Other key upcoming milestones include results from the FRIDA trial (iadademstat in FLT3+ r/r acute myeloid leukaemia; expected in Q224) and a clinical timeline update from the EVOLUTION trial (vafidemstat in schizophrenia; expected in 2024). Based on the current status of the company’s programmes and improved visibility, we have adjusted our market strategy, launch timelines and valuation across the company’s pipeline, leading to a valuation reset to €11.8/share (€15.1/share previously).

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2022A 15.7 (5.3) (6.3) (7.49) N/A N/A
2023A 14.2 (4.4) (6.0) (5.65) N/A N/A
2024E 12.9 (3.1) (4.2) (2.71) N/A N/A
2025E 33.7 16.9 15.5 29.18 5.9 5.8

Further insights

insight

Epigenetics

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free